Graf Akcie AMRN (Amarin Corp). Diskuze k akciím AMRN. Aktuální informace AMRN.

Základní informace o společnosti Amarin Corp (Akcie AMRN)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 2.01B
Hodnota podniku (EV) N/A
Tržby 620.408M
EBITDA N/A
Zisk 4.32M
Růst v tržbách Q/Q 14.17 %
Růst v tržbách Y/Y 13.63 %
P/E (Cena vůči ziskům) 517.00
Forward P/E N/A
EV/Sales 2.43
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 3.24
P/FCF N/A
Price/Book 3.20
Účetní hodnota na akcii 1.61
Hotovost na akcii 1.30
FCF vůči ceně -3.05 %
Počet zaměstnanců 2,020
Tržba na zaměstnance 307.133k
Profit margin -2.93 %
Operating margin 1.23 %
Gross margin 78.59 %
EBIT margin 1.98 %
EBITDA margin -3.99 %
EPS - Zisk na akcii 0.01
EPS - Kvartální růst 100.00 %
EPS - Očekávaný růst příští rok 50.00 %
Return on assets 0.44 %
Return on equity 0.69 %
ROIC -1.59 %
ROCE 1.83 %
Dluhy/Equity 0.54
Čistý dluh/EBITDA 91.77
Current ratio 2.69
Quick Ratio 1.95
Volatilita 3.22
Beta 0.75
RSI 51.63
Cílová cena analytiků 11
Známka akcie (dle analytiků) 1.83
Insider ownership 1.20 %
Institutional ownership 37.12 %
Počet akcií 395.302M
Procento shortovaných akcií 0.00 %
Short ratio 9.76 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 1993
Země Ireland

Finanční výsledky akcie AMRN

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$429.755$229.214$181.104$130.084$81.756$54.202
Cost Of Goods Sold$96.019$54.543$44.952$34.363$27.875$20.485
Gross Profit$333.736$174.671$136.152$95.721$53.881$33.717
Research And Development Expenses$34.392$55.9$47.158$49.975$51.062$50.326
SG&A Expenses$323.623$226.996$134.549$111.372$101.041$79.346
Other Operating Income Or Expenses------
Operating Expenses$454.034$337.439$226.659$195.71$179.978$150.157
Operating Income$-24.279$-108.225$-45.555$-65.626$-98.222$-95.955
Total Non-Operating Income/Expense$1.798$-8.124$-9.263$-10.755$-20.068$36.754
Pre-Tax Income$-22.481$-116.349$-54.818$-76.381$-118.29$-59.201
Income Taxes$0.164$0.096$13.047$9.969$-3.086$-2.837
Income After Taxes$-22.645$-116.445$-67.865$-86.35$-115.204$-56.364
Other Income------
Income From Continuous Operations$-22.645$-116.445$-67.865$-86.35$-115.204$-56.364
Income From Discontinued Operations------
Net Income$-22.645$-116.445$-67.865$-86.35$-149.059$-56.364
EBITDA$-21.776$-105.373$-42.515$-57.06$-89.152$-89.248
EBIT$-24.279$-108.225$-45.555$-65.626$-98.222$-95.955
Basic Shares Outstanding343297271212181174
Shares Outstanding343297271212181174
Basic EPS$-0.07$-0.39$-0.25$-0.41$-0.83$-0.32
EPS - Earnings Per Share$-0.07$-0.39$-0.25$-0.41$-0.83$-0.36
# 2020 2019 2018 2017 2016 2015
Current Ratio3.52952.40361.41221.91912.82963.6045
Long-term Debt / Capital-0.23242.87471.1192.26671.6782
Debt/Equity Ratio0.08240.5275-1.8841-12.856-1.905-2.6485
Gross Margin77.657376.204375.178973.58465.904762.2062
Operating Margin-5.6495-47.2157-25.1541-50.4489-120.1404-177.0322
EBIT Margin-5.6495-47.2157-25.1541-50.4489-120.1404-177.0322
EBITDA Margin-5.0671-45.9715-23.4755-43.864-109.0464-164.6582
Pre-Tax Profit Margin-5.2311-50.76-30.2688-58.7167-144.6866-109.2229
Net Profit Margin-5.2693-50.8019-37.4729-66.3802-182.3218-103.9888
Asset Turnover0.48710.59431.12070.7790.4720.3168
Inventory Turnover Ratio1.25080.94361.48551.67571.46831.4917
Receiveable Turnover3.69113.44563.99636.50915.91326.9118
Days Sales In Receivables98.8865105.931191.334756.075561.726252.8086
ROE - Return On Equity-3.8616-89.243675.8573258.362275.83463.7256
Return On Tangible Equity-3.8187-80.390192.6788484.295784.109557.2159
ROA - Return On Assets-2.5669-30.1895-41.9962-51.7069-66.5035-32.9408
ROI - Return On Investment-3.7229-58.6808-195.4299-113.4736-114.41-43.219
Book Value Per Share1.68910.4675-0.2402-0.0336-0.6955-0.5066
Operating Cash Flow Per Share0.2913-0.19730.21770.1261-0.03590.7101
Free Cash Flow Per Share0.2842-0.19740.21770.1261-0.0360.7101

Porovnání s konkurencí: Akcie AMRN

Společnost P/E PEG Růst v tržbách (roční) Růst v EPS Return on equity P/B Profit margin
AMRN 517.00 N/A 13.63 % 50.00 % 0.69 % 3.20 -2.93 %
Akcie ABBV 29.80 1.28 48.31 % 14.49 % 48.79 % 14.67 10.08 %
Akcie ALKS N/A 2.31 -5.30 % -80.77 % -5.84 % 4.70 -10.67 %
Akcie AZN 41.82 1.02 14.90 % 40.43 % 26.02 % 10.19 11.81 %
Akcie GSK 16.60 3.36 N/A % -14.00 % 29.69 % 4.85 16.86 %
Akcie TEVA N/A 0.79 -0.96 % 12.07 % -39.21 % 1.08 -23.95 %

Nedávné obchody insiderů: Akcie AMRN

Jméno Obchod Cena Objem
Aaron Berg
CHIEF COMMERCIAL OFFICER
Option
25 Feb 2021
$6.95 $771,867
John F Thero
President and CEO
Option
31 Dec 2020
$4.89 $65,878
Joseph T Kennedy
General Counsel
Option
31 Dec 2020
$4.89 $17,663
Steven B Ketchum
Chief Scientific Officer
Option
31 Dec 2020
$4.89 $14,944
Michael Wayne Kalb
SVP and CFO
Option
31 Dec 2020
$4.89 $14,944
Aaron Berg
CHIEF COMMERCIAL OFFICER
Option
31 Dec 2020
$4.89 $14,944
Steven B Ketchum
Chief Scientific Officer
Prodej
27 Jan 2021
$8.01 $3,377,248
John F Thero
President and CEO
Option
29 Jan 2021
$7.50 $1,568,783
Joseph T Kennedy
General Counsel
Option
29 Jan 2021
$7.50 $317,588
Michael Wayne Kalb
SVP and CFO
Option
29 Jan 2021
$7.50 $313,418
Aaron Berg
CHIEF COMMERCIAL OFFICER
Option
29 Jan 2021
$7.50 $118,418
Steven B Ketchum
Chief Scientific Officer
Prodej
1 Feb 2021
$8.06 $1,754,888
John F Thero
President and CEO
Option
31 Dec 2020
$4.89 $65,878
Joseph T Kennedy
General Counsel
Option
31 Dec 2020
$4.89 $17,663
Steven B Ketchum
Chief Scientific Officer
Option
31 Dec 2020
$4.89 $14,944
Michael Wayne Kalb
SVP and CFO
Option
31 Dec 2020
$4.89 $14,944
Aaron Berg
CHIEF COMMERCIAL OFFICER
Option
31 Dec 2020
$4.89 $14,944
Steven B Ketchum
Chief Scientific Officer
Prodej
27 Jan 2021
$8.01 $3,377,248
John F Thero
President and CEO
Option
29 Jan 2021
$7.50 $1,568,783
Joseph T Kennedy
General Counsel
Option
29 Jan 2021
$7.50 $317,588
Michael Wayne Kalb
SVP and CFO
Option
29 Jan 2021
$7.50 $313,418
Aaron Berg
CHIEF COMMERCIAL OFFICER
Option
29 Jan 2021
$7.50 $118,418
Steven B Ketchum
Chief Scientific Officer
Prodej
1 Feb 2021
$8.06 $1,754,888

Diskuze k akciím AMRN